Yoran Hummel, Us2.ai co-founder.

Artificial Intelligence

CW Q&A: Us2.ai’s Strain Analysis Feature

In this Cardiac Wire Q&A, we sat down with Us2.ai president Yoran Hummel to discuss Us2.ai’s soon-to-be-released automated strain analysis feature. 

Can you share a little bit about yourself and Us2.ai?

My name is Yoran Hummel. Based in the Netherlands, I’m one of three Us2.ai co-founders and the current acting president. I’ve had a long career in echocardiography for approximately 25 years doing echoes myself. Eventually, I got fed up with echo, not so much with the cardio mechanics, or the hemodynamics of echo, or even my guilty pleasure, the physics of ultrasound. I got fed up with the manual, labor-intensive work. Searching for the best images, searching for the best frames, and doing endless drawings of cavities and cardiac structures. And that’s how I ended up being a founder of this company called Us2.ai.

How would you describe Us2.ai to people who aren’t familiar with the company?

Us2.ai is a problem solver that automates the analysis of echo. It brings a tedious, 30-minute procedure back to two minutes, single click, full analysis. And when we say ‘full’, it’s full analysis with no human intervention, yet with the possibility to do everything manually. So we open up the black box approach to analysis.

One of the biggest problems that has always been an issue within echocardiography, is human variability. For example, if I measure an echocardiogram, and I remeasure it later that same day, my results will be different. This is inherent to echo. This is inherent to being a human. We are simply not machines that follow a program. 

Automation, working with Machine Learning, actually gets rid of that variability. It’s objective because it does the same thing, every time. The automated algorithm doesn’t get distracted; it simply does what it’s trained to do. This means that in longitudinal follow-up of patients, you get an objective measure through time, which helps us to track the changes more accurately. This is potentially a whole new spectrum of information from which we can learn more about cardiac disease.

Word on the street is Us2.ai will soon offer strain analysis. What is strain? Why is it important? And how is it different from conventional methods?

Strain is a measure of cardio-mechanics. It measures how the muscle of the heart works. Strain allows us to look at the muscle and at the function of the muscle. The muscle, and its function, actually dictate how the blood flows within the heart. In contrast, in conventional echo, we measure all kinds of blood-related flows, like velocities and volumes. Most of our conclusions are based on those volumetric and flow hemodynamics instead of the thing that actually causes those hemodynamics to change – the cardiac muscle. With strain, we have the opportunity to measure the cause of those hemodynamic changes directly.

How does strain analysis satisfy the needs of patients, doctors, and other stakeholders?

What we call ‘cardiac disease’ is, in most cases, a disease of the muscle. Since we now have the possibility to actually examine the function of that muscle, we are closer to the cause of the disease. 

How does it affect the work of a doctor? We are now able to detect the subtle changes in muscle function caused by disease much earlier. This potentially enables us to intervene earlier. And that’s a huge game changer of course, in cardiovascular disease, which is currently one of the biggest killers globally.

When this launches, how long until physicians will be able to use this feature in their day-to-day practice?

Immediately. Keep in mind, strain itself is already mostly accepted. However, full automation of strain is not. In a normal setting, what you need to do is find an image, then pinpoint certain landmarks on that image to then start the analysis. But the Us2 solution is a non-click solution. As long as a user provides us with the images, strain will be included in your normal reporting. So it’s not an add-on, it’s not an extra, it’s an integral part of your conventional echo.

So there’s no additional work on behalf of the physician or the person performing the echo?

None whatsoever.

How does the addition of the strain analysis fit into the company’s overall strategy?

The aim of our company is to democratize echo. Everyone can echo, that’s our tagline. And to do so, we must aim for reducing known variability in all the analyses. So adding fully automated strain is just the next step for us as a company. To make it the best clinical tool we can, we need to be able to do everything fully automated. Our first release was a good basis of structural and functional measurements. And now we’re adding on all the new things! Strain is just one of many exciting things coming. We’re working hard towards a full-blown echo with everything you could ever imagine. Fully automated!

Why do you think there is hesitancy in the healthcare sector to embrace AI solutions? 

I think the main driver is people simply think it’s this big unknown. Which is weird, because AI is everywhere already. Maybe there’s also a bit of fear factor in it. People sometimes wonder, ‘Is it going to take my job?’ What might help is to take a look at what we’re doing now in healthcare. Is that sustainable? I think most people, deep in their core, know that it isn’t. We need to embrace automation. It’s not man versus machine, it’s man and machine. This tool is not replacing you. It’s supersizing you. 

For more on Us2.ai, head over to their website.

Personalized Care Pathway for Heart Attack Prevention

More than 50% of patients who suffer a heart attack are considered “low risk” based on symptoms, but in fact do have plaque build up. Cleerly tackles the matter head-on in their 5-step care pathway for early diagnosis, informed decision making, and personalized treatment.

Transformation Through Structured Reporting 

Ready to realize the benefits of cardiovascular imaging structured reporting? Check out these quick and powerful Change Healthcare videos detailing the efficiency gains provided by structured reporting and what it takes to drive adoption.

The Wire

• Exercise Regimens in AFib Patients: Despite a substantially lower total exercise volume, 23 minutes of high-intensity interval training (HIIT) was as effective as 60 minutes of moderate to vigorous intensity continuous training (MICT) in improving outcomes in people with AFib. That’s from a randomized clinical trial that had 86 individuals with AFib perform either a twice-weekly HIIT or MICT workout. Patients in both groups improved to the same degree, achieving similar scores in quality of life and the 6MWT at 12 weeks. 

• ACC/AHA Update Aortic Disease Guideline: For the first time in 12 years, the ACC and AHA have updated the guidelines related to the diagnosis and management of aortic disease. The new guidelines emphasize the role of genetics and family screening, consistency in aorta imaging, the importance of multidisciplinary care and shared decision-making, as well as a smaller aortic diameter at which surgical intervention for aneurysms can be considered.  

• CVRx Launches Barostim NEO2: CVRx launched the second generation of its Barostim neuromodulation heart failure treatment device. Like its predecessor, the new Barostim NEO2 works by stimulating baroreceptors – sensors in the body that tell the nervous system how to regulate the heart. This helps the heart pump more efficiently, relieving heart failure symptoms. The upgraded device features a smaller implantable pulse generator, a longer battery life, and a single lead import. 

• Who Uses Wearable Devices: People who need wearable health devices (like smartwatches and fitness bands) the most appear to use them the least. An analysis of a 9.3k person survey found that people with CVD were far less likely to use wearables than the general population (18% vs. 29%). More education, higher income, and younger age were all linked to greater wearable use. On the bright side, over 80% of users at risk for CVD would be willing to share wearable-tracked health information with their health providers to improve their care (regardless of age, income, gender, education, or race).

• SGLT2i and GLP-1 RA Underuse: A new analysis of 321k patients with type 2 diabetes and atherosclerotic CVD found that uptake of SGLT2i and GLP-1 RA therapy is very low. Over a recent three year period, SGLT2i use increased from 5.8% to 12.9% and GLP-1 RA increased from 6.9% to 13.8%. While use did increase modestly after new guideline recommendations, over three quarters of patients were still not taking either (as of March 2021). The cost of these prescriptions likely contributes to the continued underuse.

• Semaglutide in Adolescents: Semaglutide (FDA-approved in adults) plus lifestyle intervention led to a “substantial reduction” in the BMI of teenagers with obesity after more than a year of weekly treatments. In the double-blind RCT, 201 teens aged 12-17 received either 2.4mg of subcutaneous semaglutide once weekly or a placebo. Both groups also received lifestyle intervention consisting of nutrition and physical activity counseling. After 68 weeks, semaglutide takers saw a 16.1% BMI reduction, while the placebo group’s BMI increased 0.6%.

• Exercise Timing: New research suggests performing moderate to vigorous activity (MVPA) in the afternoon or evening may improve blood glucose levels to a greater extent than exercising evenly throughout the day. That’s from an analysis of 775 participants (mean BMI: 26.2) who wore activity monitors for four consecutive days. MVPA in the afternoon or evening was associated with the lowest insulin resistance (a reduction of up to 25%), but not with differences in liver fat content. 

• ShockWave Win: A clinical trial found that ShockWave Medical’s intravascular lithotripsy (IVL) technology consistently improved outcomes in patients with heavily calcified peripheral artery disease (PAD). The IVL technology leverages angioplasty balloon catheters to deliver sound waves that break up calcified coronary lesions *without* harming soft tissue. In the study, 1.4k real-world PAD patients with moderate to severe calcification were treated with IVL. The premier technology consistently reduced the diameter of stenosis with no associated abrupt closure, distal embolization, or thrombotic events. 

• The Future of In-Home Ultrasound: Signify Research forecasted that ultrasound will continue to expand into patient homes, although the timing and path of this expansion is still unclear. The firm highlighted growing investments from home ultrasound vendors, but noted the unanswered questions about whether patients or professionals will perform these exams, who will pay for these devices and services, and how regulators will view this expansion. 

• CMS Final Rule: CMS issued its final rule for the 2023 Physician Fee Schedule. Here are two key changes pertaining to cardiology from the final rule: 1) The conversion factor was cut from $34.61 to $33.06, which will lead to a 1% cut in cardiology reimbursements; 2) Within electrophysiology specifically, CMS will implement relative value units for supraventricular tachycardia, ventricular tachycardia, and atrial fibrillation ablation that are a 3.7% cut compared to last year (but still 11.2% higher than what was originally proposed). 

• AI LVEF Diagnoses Adoption: A new Mayo Clinic study revealed that primary care clinicians who readily embraced AI tools (“high adopters”) identified people with low left ventricular ejection fraction (LVEF) more accurately.  Among 165 clinicians who saw 11.5k patients, high adopters were more likely to catch low EF based on ECG data compared with low adopters (odds ratio: 1.62). Age was not associated with the high-adopter group. High adopters were more often nurse practitioners or physician assistants (rather than physicians), and tended to have less complex patients.

Us2.ai’s Echo Evidence

Have more echo studies than sonographers? See how Us2.ai was able to classify, segment, and annotate echocardiographic videos with similar accuracy as expert sonographers. 

HeartFlow Analysis Streamlines Care

Faced with cath lab inefficiencies and an increased reliance on stress testing, Cone Health pursued a more advanced solution. See how the HeartFlow FFRct Analysis allowed Cone Health to improve the patient journey through streamlined CAD testing.